FDA approves MannKind Furoscix ReadyFlow autoinjector for at-home fluid overload treatment
The United States Food and Drug Administration (FDA) has approved MannKind Corporation’s Furoscix ReadyFlow, a prefilled autoinjector that delivers 80 milligrams of subcutaneous furosemide in about ten seconds for adults experiencing edema associated with chronic heart failure or chronic kidney disease. The July 24 approval creates a faster alternative to the existing Furoscix On-body Infusor,